• Jeremy Ong, Patricia Walker, Kasha P Singh, Emma Bishop, and Kay Htun.
• Department of Haematology, Peninsula Health, Melbourne, Victoria, Australia.
• Intern Med J. 2022 Jan 1; 52 (1): 37-41.

BackgroundVenous thromboembolic (VTE) complications appear common in hospitalised COVID-19 patients, particularly among critically ill patients in intensive care units. However, there is significant heterogeneity in the reported use of thromboprophylaxis.AimsThe primary objective was to determine rates of symptomatic VTE in hospitalised COVID-19 patients. Secondary objectives were to assess adherence to an institutional risk-adapted thromboprophylaxis guideline, and rates of bleeding complications.MethodsA retrospective, single-centre, cohort study was performed in consecutive hospitalised COVID-19 patients over a 6-month period (March to August 2020). Enoxaparin was used as thromboprophylaxis in all patients without a contraindication, with dose adjusted according to disease severity, weight and renal function.ResultsAmong 86 hospitalised COVID-19 patients, no VTE were identified. Eighty-one (94%) patients received anticoagulation, with 90% adherence to institutional thromboprophylaxis guidelines. Four bleeding events occurred, with one clinically relevant non-major bleeding event and three minor bleeding events.ConclusionLow rates of VTE were identified in hospitalised COVID-19 patients using a risk-adapted thromboprophylaxis protocol.© 2021 Royal Australasian College of Physicians.

16 keywords...

hide…